| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | RAF265 | CTRPv2 | pan-cancer | AAC | 0.066 | 0.1 |
| mRNA | BI-2536 | CTRPv2 | pan-cancer | AAC | 0.05 | 0.1 |
| mRNA | ML203 | CTRPv2 | pan-cancer | AAC | -0.061 | 0.1 |
| mRNA | GDC-0941 | CTRPv2 | pan-cancer | AAC | -0.058 | 0.1 |
| mRNA | triazolothiadiazine | CTRPv2 | pan-cancer | AAC | 0.047 | 0.1 |
| mRNA | momelotinib | CTRPv2 | pan-cancer | AAC | 0.054 | 0.1 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.058 | 0.1 |
| mRNA | Doxorubicin | gCSI | pan-cancer | AAC | -0.08 | 0.1 |
| mRNA | BRD-K94991378 | CTRPv2 | pan-cancer | AAC | 0.061 | 0.1 |
| mRNA | OSI-930 | CTRPv2 | pan-cancer | AAC | -0.056 | 0.1 |